الفهرس 
Intravenous immunoglobulins in neonates
AbstractOnly 14 pages are availabe for public view
 |  | from | 129 |  |  |
| | | from | 129 | | |
Abstract
Background Intravenous immunoglobulins (IVIGs) are scarce biological products used in a broad variety of disorders. (IVIG) is a concentrated, highly purified solution of immunoglobulin (IgG) derived from large pools of human plasma. It is a useful treatment for isoimmune hemolytic jaundice in neonates with minimal side effects. Aim: the purpose of the present study is to detect the efficacy and the incidence of various adverse effects IVIG in neonates.Patients and methods: This study included 120 neonates who were admitted in the NICU due to indirect hyperbilirubinemia in the intensive care unit (NICU) of Cairo University hospitals from April 2016 till April 2017.The neonates were divided into two groups: group A: Sixty neonates receiving IVIG in the NICU due to isoimmune hemolytic jaundice group B: Matched age, sex and the severity of isoimmune hemolytic jaundice admitted neonates were taken to rule out if hemolysis followed intravenous immunoglobulin infusion or from the primary disease disorder. All cases were subjected to complete history taking, full clinical examination and laboratory investigations.Results: IVIG reduce the need for exchange transfusion. Only 6 cases in group A needed exchange transfusion (10%) of cases while in group B 30 cases needed exchange transfusion (50%) of cases with p value <0.01. Side effect was mild and transient in the form of transient hypertension, vomiting, fever, erythema in the face.Conclusion: IVIG is very useful for treatment of isoimmune hemolytic jaundice which significantly reduces the need for exchange transfusion with mild and transient side effects